An observational study in Severe Combined Immunodeficiency, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruiting at 1 site in United States. Open to participants aged 6 Months to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Severe Combined Immunodeficiency with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Severe Combined Immunodeficiency · United States.
Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2004, is one of 12 observational ones, and was the 7th registered.
59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.
Browse Severe Combined Immunodeficiency studies →9 of the 38 studies in Severe Combined Immunodeficiency with a site in United States are open now. Recruiting first, the newest first:
Paul Szabolcs · Sites in United States
Ages 5–40
Paul Szabolcs · Sites in United States
Ages 2 mo–60 yrs
University of California, San Francisco · Sites in United States
Ages 2 mo+
Paul Szabolcs · Sites in United States
Ages 2 mo–55 yrs
University of California, Los Angeles · Sites in United States, United Kingdom
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Severe Combined Immunodeficiency studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 6 Months to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 3
First in 1990; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 19 observational studies indexed under Severe Combined Immunodeficiency.
Median enrollment 9 across the 24 interventional studies, 88 across the 12 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 38 have an industry lead sponsor. The 10 most frequent:
National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,144 studies on the registry; 71 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 51 (88%) have results posted.
National Heart, Lung, and Blood Institute (NHLBI) has 3 studies filed under Severe Combined Immunodeficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Severe Combined Immunodeficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01852370Paul SzabolcsSequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases | 2026-11 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03597594St. Jude Children's Research HospitalHaplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID).
Patients with immunodeficiencies may be eligible for this study. Candidates include:
Relatives of patients will also be studied.
Participants will have blood samples collected for genetic analysis in studies related to SCID at the National Institutes of Health and other institutions.
...
The goal of this project is to identify the genetic basis of new forms of inherited immunodeficiency. The particular focus relates to cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 that share the common cytokine receptor (Gamma) chain, (Gamma c), and to molecules that are important for signaling or gene regulation in response to these cytokines, although other causes of inherited immunodeficiency are also encompassed.
Primary clinical
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Index cases to be included are those with diminished numbers of T cells and/or NK cells and/or B cells or other immune cells or those who have normal numbers of T cell, B cells, NK cells and other immune cells but diminished function of one or more immune cells. Relatives of affected individuals may also be studied
EXCLUSION CRITERIA:
18 years of age or older
Patients (index cases), 6 months of age or older
Siblings, 6 months of age or older
To identify forms of inherited immunodeficiency resulting from mutation of yc dependent cytokines, components of their receptors, or signaling molecules in their pathways
In an effort to determine the cause of the immunodeficiency, we will perform studies that may include but not be limited to evaluating the levels of expression of protein and/or mRNA, obtaining DNA sequence data, performing epigenetic studies, and evaluating biological function using cellular, biochemical, or other molecular studies.
Time frame: ongoing
Plan to share: Undecided
Started Apr 2004 (actual).
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe Combined Immunodeficiency →
National Heart, Lung, and Blood Institute (NHLBI) →